Merck surpasses Keytruda strength first-quarter expectations.

Published Date: 29 Apr 2023

As a result of the success of its top-selling cancer immunotherapy Keytruda and its human papillomavirus vaccine Gardasil, Merck on Thursday reported better-than-anticipated results for the first quarter.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

2.

New drug resistance mechanism in melanoma leptomeningeal disease revealed by study.

3.

Research finds stark disparities in treatment and survival time for people with pancreatic cancer

4.

Tumor characteristics found to differ for melanomas in children, teens and young adults

5.

Relationship-building key to addressing oncologist shortages in rural care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot